Trials / Recruiting
RecruitingNCT05667194
Phase 1 Trial of KH617
A Phase 1 Study to Assess the Safety ,Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of KH617 After SAD and MAD Administration for Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Sichuan Honghe Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
KH617 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KH617 | KH617 is s freeze-dried powder injection |
Timeline
- Start date
- 2022-12-26
- Primary completion
- 2030-09-01
- Completion
- 2031-08-01
- First posted
- 2022-12-28
- Last updated
- 2024-11-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05667194. Inclusion in this directory is not an endorsement.